Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. FDX
2. CBRS
3. KBH
4. HON
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. USO

Go back to Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Teva Pharma (TEVA) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY25 Revenue Guidance

July 30, 2025 7:06 AM EDT

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.66, $0.03 better than the analyst estimate of $0.63. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.28 billion.

GUIDANCE:

Teva Pharma sees FY2025 revenue of $16.8-17.2 billion, versus the consensus... More